Larry Kwak, PhD
Hematology · Duarte, CANPI 1134215817
Payments from drug & device makers
Across 15 payments — averaging $4922.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$22K
- Janssen Research & Development, LLC$15K
- CSL Behring$10K
- Blueprint Medicines Corporation$10K
- Sarepta Therapeutics, Inc.$10K
- Genentech, Inc.$5K
- plus $3K from 3 others
Across 1 payment — averaging $25,944 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celltrion, Inc.$26K
What the payments were for
- Consulting fees$72,53398%
- Travel & lodging$8311%
- Food & beverage$4661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $21,563 |
| Janssen Research & Development, LLC | 1 | $15,000 |
| CSL Behring | 1 | $10,000 |
| Blueprint Medicines Corporation | 1 | $10,000 |
| Sarepta Therapeutics, Inc. | 1 | $10,000 |
| Genentech, Inc. | 6 | $4,586 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,640 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Tempus AI, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$15,000
- Venclexta$4,586
- Non-Covered Product$4,586
How this compares
$73,830 in reported general payments places this provider in the 50th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Vinod PullarkatDuarte$10M
- Ibrahim AldossDuarte$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.